Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Endo Inc NDOI

Healthcare
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical... see more

Recent & Breaking News (OTCQX:NDOI)

    Endo Launches ADRENALIN® Ready-to-Use Premixed Bag, the First and Only FDA-Approved, Manufacturer-Prepared Epinephrine Premixed IV Bag

    PR Newswire 6 hours ago

    John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX® (collagenase clostridium histolyticum)

    PR Newswire 12 days ago

    Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling

    PR Newswire 13 days ago

    Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

    PR Newswire November 15, 2024

    Endo Reports Third-Quarter 2024 Financial Results and Reaffirms 2024 Financial Expectations

    PR Newswire November 5, 2024

    Endo Announces Successful Term Loan Repricing

    PR Newswire October 29, 2024

    Endo Announces Seven New Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting

    PR Newswire October 17, 2024

    Endo to Host Investor Call on Third-Quarter 2024 Financial Results

    PR Newswire October 15, 2024

    Endo Presents Data at the American Orthopaedic Foot & Ankle Society Annual Meeting

    PR Newswire September 13, 2024

    ENDO ANNOUNCES CEO TRANSITION

    PR Newswire August 27, 2024

    ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS

    PR Newswire August 27, 2024

    Endo Presents New Data at the American Podiatric Medical Association Annual Meeting

    PR Newswire August 8, 2024

    Endo to Host Investor Call on Second Quarter 2024 Financial Results

    PR Newswire August 7, 2024

    Endo Announces Effectiveness of Form S-1 Registration Statement for Existing Shares

    PR Newswire July 31, 2024

    Endo Releases Annual Corporate Responsibility Report

    PR Newswire July 29, 2024

    Endo USA, Inc. Issues Voluntary, Nationwide Recall of One Lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Lot Number 550147301 Due to Mislabeling: Incorrect Strength on Product Carton

    PR Newswire July 16, 2024

    Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC®

    PR Newswire July 15, 2024

    Endo Files Registration Statement with SEC, Advancing Planned Move to NYSE

    PR Newswire July 12, 2024

    Endo Announces Commencement of OTCQX Trading

    PR Newswire June 28, 2024

    OTC Markets Group Welcomes Endo, Inc. to OTCQX

    GlobeNewswire June 28, 2024